|Bid||1,399.00 x 0|
|Ask||1,440.00 x 0|
|Day's range||1,398.40 - 1,421.00|
|52-week range||1,190.80 - 1,619.20|
|Beta (5Y monthly)||0.40|
|PE ratio (TTM)||16.33|
|Earnings date||27 Oct 2021|
|Forward dividend & yield||0.80 (5.64%)|
|Ex-dividend date||19 Aug 2021|
|1y target est||1,644.50|
Dr. Michael Gonzalez, Emergency Medicine Physician & Assistant Professor at Baylor College of Medicine, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
Pfizer (PFE), Merck (MRK) and others announce Q2 results. FDA approves AbbVie's (ABBV) new antibiotic injection and expands use of Merck's Keytruda and Glaxo's Shingrix and Nucala.
LONDON, July 29, 2021--GSK announces FDA approval for Nucala (mepolizumab) for use in adults with chronic rhinosinusitis with nasal polyps.